We are live on
!
Find out more
Aberdeen Group Portfolio holdings
AUM
$61.9B
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
+5.07%
1 Year Est. Return
+29.81%
3 Year Est. Return
+93.17%
5 Year Est. Return
+119.65%
10 Year Est. Return
–
AUM
$64.6B
AUM Growth
+$1.37B
(+2.2%)
Cap. Flow
-$686M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
38.17%
Holding
995
New
43
Increased
362
Reduced
491
Closed
59
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nu Holdings
NU
|
+$36.3M |
| 2 |
SCHW
Charles Schwab
SCHW
|
+$36.1M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$35.6M |
| 4 |
Danaher
DHR
|
+$30.5M |
| 5 |
uniQure
QURE
|
+$28.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$93.5M |
| 2 |
Mercado Libre
MELI
|
+$86M |
| 3 |
Microsoft
MSFT
|
+$62.9M |
| 4 |
Apple
AAPL
|
+$55.6M |
| 5 |
BioMarin Pharmaceuticals
BMRN
|
+$48.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.59% |
| 2 | Healthcare | 13.39% |
| 3 | Consumer Discretionary | 11.41% |
| 4 | Communication Services | 11.25% |
| 5 | Financials | 10.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
651
KB Home
KBH
$3.5B
| $7.7M | 0.01% |
136,526
+28,381
| +26% | +$1.75M |
|
652
Guardant Health
GH
$19.1B
| $7.67M | 0.01% |
75,124
-40,577
| -35% | -$3.63M |
|
653
Zillow
Z
$7.78B
| $7.53M | 0.01% |
110,373
-200
| -0.2% | -$14.5K |
|
654
Immatics
IMTX
$1.23B
| $7.5M | 0.01% |
714,569
-74,877
| -9% | -$756K |
|
655
Align Technology
ALGN
$12.9B
| $7.45M | 0.01% |
47,732
-6,717
| -12% | -$963K |
|
656
Tenet Healthcare
THC
$22.2B
| $7.4M | 0.01% |
37,237
| – | – |
|
657
News Corp Class A
NWSA
$15.6B
| $7.28M | 0.01% |
278,624
+310
| +0.1% | +$8.13K |
|
658
International Paper
IP
$22.6B
| $7.25M | 0.01% |
183,957
+11,690
| +7% | +$481K |
|
659
ArcBest
ARCB
$3.16B
| $7.24M | 0.01% |
+97,587
| New | +$6.94M |
|
660
Petrobras
PBR
$120B
| $7.22M | 0.01% |
608,893
+322,821
| +113% | +$3.94M |
|
661
BioCryst Pharmaceuticals
BCRX
$2.42B
| $7.13M | 0.01% |
+913,593
| New | +$6.6M |
|
662
Alcon
ALC
$34B
| $7.1M | 0.01% |
90,134
+55,808
| +163% | +$4.3M |
|
663
Pultegroup
PHM
$25.2B
| $7.09M | 0.01% |
60,488
-555
| -0.9% | -$68.1K |
|
664
Lennar Class A
LEN
$20.4B
| $7.09M | 0.01% |
68,936
-1,255
| -2% | -$152K |
|
665
Builders FirstSource
BLDR
$7.29B
| $7.03M | 0.01% |
68,326
-704
| -1% | -$79.1K |
|
666
Baxter International
BAX
$12.8B
| $6.99M | 0.01% |
365,915
-51,608
| -12% | -$1.03M |
|
667
Tyson Foods
TSN
$21.5B
| $6.83M | 0.01% |
116,588
-23,516
| -17% | -$1.29M |
|
|
XIFR
668
XPLR Infrastructure LP
XIFR
$1.04B
| $6.8M | 0.01% |
680,451
-3,393
| -0.5% | -$32.9K |
|
669
Kanzhun
BZ
$7.19B
| $6.75M | 0.01% |
331,329
+2,861
| +0.9% | +$61.8K |
|
670
Sera Prognostics
SERA
$80.3M
| $6.73M | 0.01% |
2,279,699
| – | – |
|
671
Charter Communications
CHTR
$17.3B
| $6.65M | 0.01% |
31,875
-339
| -1% | -$76.3K |
|
672
Healthcare Realty
HR
$7.56B
| $6.63M | 0.01% |
391,201
+81,273
| +26% | +$1.45M |
|
673
CareDx
CDNA
$1.83B
| $6.51M | 0.01% |
+345,308
| New | +$5.78M |
|
674
CF Industries
CF
$19.6B
| $6.19M | 0.01% |
80,027
-15,925
| -17% | -$1.31M |
|
675
LyondellBasell Industries
LYB
$19.5B
| $6.1M | 0.01% |
140,959
+6,738
| +5% | +$305K |
|
Similar funds
Aberdeen Group's Q4 2025 Portfolio in Review
As of Q4 2025, Aberdeen Group held 995 positions worth $64.6B, up 2.2% from $63.2B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Aberdeen Group's Q4 2025 filing shows 43 new, 362 increased, 491 reduced and 59 closed positions. Its largest new stake was Praxis Precision Medicines: 134,992 shares worth $39.8M. The largest sale was Eli Lilly, an estimated $93.5M.
By sector, the portfolio is most concentrated in Technology at 33% of assets, down from 33% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Aberdeen Group's largest Q4 2025 buy was Praxis Precision Medicines: 134,992 shares worth $39.8M.
- Aberdeen Group added most to Nu Holdings in Q4 2025, an estimated $36.3M increase.
- Aberdeen Group's biggest Q4 2025 reduction was Eli Lilly, cutting an estimated $93.5M.
- Aberdeen Group fully exited BioMarin Pharmaceuticals in Q4 2025, selling an estimated $48.9M.
- Aberdeen Group's ten largest holdings make up 38% of its $64.6B portfolio in Q4 2025.
- Aberdeen Group opened 43 new positions and closed 59 in Q4 2025.
- Aberdeen Group's portfolio value rose 2.2% quarter-over-quarter to $64.6B.
Based on Aberdeen Group's 13F filing for Q4 2025, filed 16 Jan 2026.